Core Viewpoint - Synthetic biology concept stocks are experiencing significant upward movement, with notable gains in several companies [1] Group 1: Company Performance - Chuaning Biological (301301) reached a 20% daily limit increase [1] - Bawi Co., Ltd. saw an increase of over 20% [1] - Toxin Pharmaceutical (301089) rose by more than 10% [1] - Jindawei (002626), Oukang Pharmaceutical, and Weilan Biological (603739) also experienced upward trends [1] Group 2: Market Activity - There is a notable influx of dark pool funds into these stocks [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，伊犁川宁生物技术股份有限公司（以下 简称"公司"）将参加由新疆上市公司协会根据新疆证监局工作部署，联合深圳 市全景网络有限公司举办的"2025 年新疆辖区上市公司投资者网上集体接待日 活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 5 月 23 日（周五）15:00-17:30。届时公司 高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告。 证券代码：301301 证券简称：川宁生物 公告编号：2025-026 伊犁川宁生物技术股份有限公司 关于参加新疆辖区上市公司2025年投资者 网上集体接待日活动的公告 伊犁川宁生物技术股份有限公司董事会 2025 年 5 月 13 ...

四川省成都市高新区天府大道北段 966 号天府国际金融中心南塔 25 层-26 层 邮编：610041 25-26/F, South Tower of Tianfu International Finance Center, 966 North Tianfu Avenue, High-tech Zone, Chengdu, Sichuan 610041, P. R. China 电话/Tel : +86 28 6208 8001 传真/Fax : +86 28 6208 8111 www.zhonglun.com 北京中伦（成都）律师事务所 关于伊犁川宁生物技术股份有限公司 法律意见书 5. 公司本次股东大会参会股东登记文件和凭证资料； 2024 年年度股东大会的 法律意见书 致：伊犁川宁生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）及《上市公司股东会规则》等法律、法规 及规范性文件的规定，北京中伦（成都）律师事务所（以下简称"本所"）指派 律师出席了伊犁川宁生物技术股份有限公司（以下简称"公司"）2024 年年度股 东大会（ ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-025 伊犁川宁生物技术股份有限公司 2024年年度股东大会决议公告 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 3、本公告中百分比例均保留 4 位小数，若其各分项数值之和与合计数值存 在尾差，均为四舍五入原因造成。 一、会议召开和出席情况 （一）召开情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司董事会 3、股东大会的主持人：董事长刘革新先生 4、会议召开时间： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 （1）现场会议召开时间：2025 年 5 月 13 日 15:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 5 月 13 日 9:15-9:25、9:30-11:30 和 13:00-15:00 期间任意时间；通 过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 5 月 13 日 9:15- 15:00 期间任意时间。 5、现场会议召开地点： ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-024 根据《公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》和《公司章程》的相关规定，段胜国先生的辞职报告自送达 公司董事会之日起生效。 段胜国先生在担任公司副总经理期间恪尽职守、勤勉尽责，公司及董事会对 段胜国先生任职期间为公司所做的贡献表示衷心感谢！ 特此公告。 伊犁川宁生物技术股份有限公司董事会 关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"）董事会于近日收到公 司副总经理段胜国先生的书面辞职报告，段胜国先生因到龄退休提请辞去公司所 有职务，上述职务原定任期届满之日为 2026 年 5 月 4 日。辞职后将不再担任公 司其他任何职务。目前其所负责的相关工作已顺利交接，辞职后不会影响公司正 常生产经营活动。 2025 年 5 月 6 日 伊犁川宁生物技术股份有限公司 ...

Investment Rating - The report maintains a "Recommended" rating for the company [6][8]. Core Views - The company achieved a revenue of 5.76 billion yuan in 2024, representing a year-on-year growth of 19.4%, and a net profit attributable to shareholders of 1.4 billion yuan, up 48.9% year-on-year [3]. - In Q1 2025, the company reported a revenue of 1.3 billion yuan, a decline of 14.9% year-on-year, and a net profit of 290 million yuan, down 18.3% year-on-year [3][5]. - The strong performance in 2024 was driven by robust growth in the main business, particularly in pharmaceutical intermediates, with a revenue of 5.4 billion yuan, up 19.5% year-on-year [4]. - The company is expected to see improvements in performance throughout 2025, with a focus on maintaining price stability in key products and leveraging AI technology for cost reduction [5][6]. Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 5.76 billion yuan, with a net profit of 1.4 billion yuan, and a gross margin of 36.39% [7][11]. - The forecast for 2025 indicates a slight revenue increase to 5.88 billion yuan, with net profit expected to remain stable at 1.41 billion yuan [7][11]. Business Segments - The pharmaceutical intermediates segment showed strong growth, with key products like penicillin intermediates and cephalosporin intermediates experiencing significant revenue increases [4]. - The company is expanding its synthetic biology segment, with several products entering production, indicating potential for future growth [6]. Future Outlook - The company is projected to maintain stable profit levels from 2025 to 2027, with net profits of 1.41 billion yuan in 2025 and gradually increasing to 1.46 billion yuan by 2027 [6][7]. - The anticipated PE ratios for the forecasted years are 19 for 2025 and 18 for 2026 and 2027, reflecting a stable valuation outlook [7][11].

证券代码：301301 证券简称：川宁生物 公告编号：2025-022 伊犁川宁生物技术股份有限公司 第二届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（以下简称"公司"）第二届监事会第九次 会议通知于 2025 年 4 月 18 日以专人送达、电子邮件和电话通知的方式发出，会 议于 2025 年 4 月 28 日上午 11 点在公司会议室以现场表决方式召开。会议应出 席监事 3 人，实际出席监事 3 人，会议由监事会主席杨帆先生主持。本次会议的 召集和召开程序符合《中华人民共和国公司法》等有关法律、行政法规、部门规 章、规范性文件和《公司章程》的相关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，以书面记名投票表决方式通过以下决议： （一）以 3 票同意，0 票反对，0 票弃权，审议通过了《关于审议公司 2025 年第一季度报告的议案》 监事会对公司 2025 年第一季度报告进行了认真严格的审核后认为：公司 2025 年第一季度报告的编制和审议程序符合法律、法规及《公司章 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-021 伊犁川宁生物技术股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 伊犁川宁生物技术股份有限公司（以下简称"公司"）第二届董事会第十次 会议通知于 2025 年 4 月 18 日以专人送达、电子邮件和电话通知的方式发出，会 议于2025年4月28日上午10点在公司会议室以现场结合通讯的表决方式召开。 会议应出席董事 7 人，实际出席董事 7 人，会议由董事长刘革新先生主持，公司 全体监事及高级管理人员列席了会议。本次会议的召集和召开程序符合《中华人 民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公司章程》 的相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，以书面记名投票表决方式通过以下决议： （一）以 7 票同意，0 票反对，0 票弃权，审议通过了《关于公司 2025 年第 一季度报告的议案》 公司董事会认真审议了《伊犁川宁生物技术股份有限公司 2025 年第一季度 报告》， ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,296,949,550.16, a decrease of 14.85% compared to ¥1,523,218,164.00 in the same period last year[7] - Net profit attributable to shareholders was ¥288,218,532.72, down 18.26% from ¥352,614,874.42 year-on-year[7] - Basic earnings per share were ¥0.13, reflecting an 18.75% decline from ¥0.16 in the same quarter last year[7] - Net profit for the current period was ¥288,206,596.52, down 18.3% from ¥352,626,111.92 in the previous period[27] Cash Flow - The cash flow from operating activities decreased significantly by 56.91%, amounting to ¥116,584,540.52 compared to ¥270,569,372.13 in the previous year[15] - Operating cash inflow for the current period was $648,163,490.34, down 18.2% from $792,326,034.25 in the previous period[30] - Net cash flow from operating activities decreased to $116,584,540.52, a decline of 56.9% compared to $270,569,372.13 in the prior period[31] - Cash outflow from investment activities totaled $422,965,903.29, significantly higher than $80,063,954.60 in the previous period[31] - Net cash flow from investment activities was -$222,501,544.38, worsening from -$79,956,654.60 in the prior period[31] - Cash flow from financing activities resulted in a net outflow of -$28,751,355.04, compared to -$66,575,155.57 in the previous period[31] - The ending balance of cash and cash equivalents was $952,641,363.26, an increase from $883,122,418.32 in the previous period[32] Assets and Liabilities - Total assets increased by 1.70% to ¥10,732,543,256.83 from ¥10,553,579,961.17 at the end of the previous year[7] - Total liabilities decreased to ¥2,525,346,199.76 from ¥2,637,164,117.24, a reduction of about 4.2%[24] - Non-current liabilities decreased to ¥553,278,437.67 from ¥689,629,227.58, a drop of about 19.7%[24] - The total non-current assets decreased to CNY 6,316,164,332.27 from CNY 6,409,356,087.63, a decline of approximately 1.5%[22] Equity - The total equity attributable to shareholders increased by 3.68% to ¥8,188,380,183.44 from ¥7,897,587,034.11 at the end of the previous year[7] - The company's retained earnings increased to ¥2,349,151,220.87 from ¥2,060,932,688.15, an increase of approximately 14.0%[24] Research and Development - Research and development expenses surged by 140.34% to ¥40,094,047.08, up from ¥16,682,182.70 year-on-year, indicating a strong focus on innovation[13] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[19] Investments - The company reported a significant increase in long-term equity investments by 139.78%, reaching ¥37,895,227.74, attributed to additional capital injections into joint ventures[12] - Long-term equity investments rose to CNY 37,895,227.74 from CNY 15,804,416.14, showing a significant increase of about 139.5%[22] Operational Costs - Total operating costs decreased to ¥947,594,552.57 from ¥1,098,639,822.39, a decline of approximately 13.7%[26] - The company experienced a 106.68% rise in selling expenses, totaling ¥7,951,719.02, primarily due to increased promotional and hospitality costs[13] Miscellaneous - The company has developed new data resources, with development expenditures recorded at CNY 1,000,000.00, which was not present in the previous period[22] - The company has not disclosed any significant mergers or acquisitions during this reporting period[19] - The company did not conduct an audit for the first quarter report[33]

Core Viewpoint - Chuaning Biological achieved significant growth in 2024, with a revenue of 5.758 billion yuan, a year-on-year increase of 19.38%, and a net profit of 1.4 billion yuan, up 48.88% [1] Group 1: Financial Performance - The company reported a basic earnings per share of 0.63 yuan, reflecting a 50% year-on-year increase [1] - The growth in performance is attributed to increased sales and prices of cephalosporin products, improved production processes reducing costs, and a decrease in interest expenses due to reduced debt [1] Group 2: Technological Advancements - Chuaning Biological has integrated AI technology into its production processes, leading to a 20% reduction in production cycle time for antibiotic intermediates and a 10% decrease in costs [2] - The company invested 167 million yuan in R&D in 2024, focusing on over 10 synthetic biology pipelines, achieving breakthroughs such as the mass production of synthetic biological compound with a purity of 99.9% [2][3] Group 3: Product Portfolio and Market Outlook - The main products for 2024 include thiocyanate erythromycin, cephalosporin intermediates, penicillin intermediates, with revenue contributions of 32.35%, 24.96%, 41.95%, and 0.74% respectively [3] - Price trends indicate that thiocyanate erythromycin prices are steadily increasing, while cephalosporin prices are stable with slight fluctuations expected, and penicillin prices have stabilized after facing pressure [3][4] Group 4: AI Integration and Production Efficiency - The introduction of AI has significantly enhanced production efficiency, with an average yield increase of 3%-5% for thiocyanate erythromycin through optimized fermentation processes [4] - The company plans to extend AI technology across its entire product line, aiming to improve overall production system efficiency and build a comprehensive intelligent system covering all R&D scenarios [4]